Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes
  • CME

Credits Available
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: July 21, 2021 Expiration: July 20, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly
Javier Cortes, MD, PhD
Stephen R. D. Johnston, MA, FRCP, PhD
Sara Tolaney, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Understand the medical need for new targeted therapies to treat patients with HR+/HER2- EBC and a higher risk of recurrence along with the underlying factors affecting the decision-making process for patients and potential barriers to adoption of novel treatment options
  • Appraise current/emerging published data and consensus-based guidelines to inform the use of biomarkers and genomic classifiers to assess risk of recurrence
  • Individualize the selection of systemic therapy for appropriate patients with HR+/HER2- EBC to include CDK4/6 inhibitors with or without endocrine therapy
  • Develop strategies to anticipate, monitor, and manage adverse events with current and emerging therapies for HR+/HER2- EBC to support quality of life and continuation of treatment
  • Identify patients with HR+/HER2- EBC eligible for enrollment on ongoing clinical studies investigating novel therapies

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Javier Cortes, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Athenex, Bioasis, Biothera, Boehringer Ingelheim, Celgene, Cellestia, Clovis Oncology, Daiichi Sankyo, Erytech, GlaxoSmithKline, Leuko, Lilly, Kyowa Kirin, Merck Sharp & Dohme, Merus, Polyphor, Roche, Seattle Genetics, and Servier; has received funds for research support from Ariad, AstraZeneca, Baxalta GmbH/Servier Affaires, Bayer, Eisai, F. Hoffmann-La Roche, Guardant, Merck Sharp & Dohme, Pfizer, Piqur, Puma, and Roche; has received fees for non-CME/CE services from Celgene, Daiichi Sankyo, Eisai, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Samsung Bioepis; has received other financial or material support from Daiichi Sankyo, Eisai, Novartis, Pfizer, and Roche; and has ownership interest in MedSIR.
Stephen R. D. Johnston, MA, FRCP, PhD

Professor of Breast Cancer Medicine
Breast Unit
Department of Medicine
Royal Marsden Hospital
London, United Kingdom

Stephen R. D. Johnston, MA, FRCP, PhD, has disclosed that he has received consulting fees from AstraZeneca, Lilly, Novartis, Pfizer, and Puma Biotechnology; funds for research support from AstraZeneca, Lilly, Novartis, Pfizer, Puma, and Roche/ Genentech; and fees for non-CME/CE services from AstraZeneca, Eisai, Novartis, Pfizer, and Roche/Genentech.
Sara Tolaney, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women's Cancer
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician

Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara Tolaney, MD, MPH, has disclosed that she has received funds for research support paid to her institution AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Immunomedics/Gilead Sciences, Lilly, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics and consulting fees from 4D Pharm, AstraZeneca, Athenex, Bristol-Myers Squibb, Certara, Cytom, Daiichi Sankyo, Eisai, Ellipses, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin, Lilly, Merck, Mersana, Nanostring, Nektar, Novartis, Odonate, OncoPep, Pfizer, Puma, Samsung Bioepsis, Sanofi, and Seattle Genetics.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational curriculum is intended for medical oncologists, breast surgeons, and other healthcare professionals involved in the treatment of breast cancer.

Goal

The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to plan individualized treatment for patients with HR+/HER2- EBC.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 21, 2021, through July 20, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes
  • CME

Loading...
Watch this on-demand webcast of a live CCO webinar where global experts discuss the latest data on CDK4/6 inhibitors in the treatment of patients with early-stage HR+/HER2- breast cancer.
Javier Cortes, MD, PhD
Stephen R. D. Johnston, MA, FRCP, PhD
Sara Tolaney, MD, MPH
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: July 21, 2021 Expiration: July 20, 2022

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Interactive online tool with strategies to assess and manage AEs associated with oral targeted therapy for HR+, HER2– breast cancer, from Clinical Care Options

Donna M. Fitzgerald, PA-C, MPAS Matthew P. Goetz, MD Marissa Marti, APRN, AGNP-C, AOCNP Joyce O'Shaughnessy, MD Laura M. Spring, MD Released: September 14, 2021

Downloadable slideset with the latest expert insights on CDK4/6 inhibitors for HR+/HER2- breast cancer, from Clinical Care Options (CCO)

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: August 24, 2021

Key takeaways from international and US experts on CDK4/6 inhibitors for HR+/HER2- early breast cancer, from Clinical Care Options (CCO)

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Released: August 17, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue